EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood endocan as a biomarker for breast cancer recurrence

Kentaro Daiki, Yoko Kanada, Aya Nagata, Kanae Taruno, Katsuhide Igarashi, Toshiko Yamochi, Hirotaka Ota, Fumiaki Sato, Seigo Nakamura, Yoshinori Kato

Cancer Biomarkers · 2024

DOI: 10.3233/cbm-240034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biomarkers, 2024. Verfasst von Kentaro Daiki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Proteoglycans, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients’ blood. OBJECTIVE: This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers. METHODS: Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3). RESULTS: Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan. CONCLUSIONS: Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorProteoglycansNeoplasm Recurrence, LocalNeoplasm ProteinsHumansFemaleAnimalsMiceMiddle AgedAgedMucin-1Cell Line, TumorAdult

Stichwörter der Autor:innen

Endocananimal modelsbiomarkerclinical studyrecurrence

Substanzen

ESM1 protein, humanBiomarkers, TumorProteoglycansNeoplasm ProteinsMucin-1

Autor:innen und Institutionen

  • Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
  • Department of Breast Surgical Oncology, Tokyo Rosai Hospital, Tokyo, Japan.
  • Department of Breast Surgical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Institute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan.
  • Laboratory of Biofunctional Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
  • Department of Pathology, Showa University School of Medicine, Tokyo, Japan.

Zitieren

APA

Daiki, K., Kanada, Y., Nagata, A., Taruno, K., Igarashi, K., Yamochi, T., Ota, H., Sato, F., Nakamura, S., & Kato, Y. (2024). Blood endocan as a biomarker for breast cancer recurrence. Cancer Biomarkers. https://doi.org/10.3233/cbm-240034

Vancouver

Daiki K, Kanada Y, Nagata A, Taruno K, Igarashi K, Yamochi T, et al. Blood endocan as a biomarker for breast cancer recurrence. Cancer Biomarkers. 2024. doi:10.3233/cbm-240034

BibTeX
@article{Daiki2024,
  author = {Daiki, Kentaro and Kanada, Yoko and Nagata, Aya and Taruno, Kanae and Igarashi, Katsuhide and Yamochi, Toshiko and Ota, Hirotaka and Sato, Fumiaki and Nakamura, Seigo and Kato, Yoshinori},
  title = {Blood endocan as a biomarker for breast cancer recurrence},
  journal = {Cancer Biomarkers},
  year = {2024},
  doi = {10.3233/cbm-240034}
}
Kostenlos starten →